Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | – | -$8,448 | -$40,935 | -$26,512 |
| Dep. & Amort. | – | $794 | $1,440 | $1,520 |
| Deferred Tax | – | $0 | $0 | -$531 |
| Stock-Based Comp. | – | $935 | $1,624 | $2,172 |
| Change in WC | – | -$1,205 | -$4,015 | $1,405 |
| Other Non-Cash | – | -$7,278 | $13,876 | -$4,697 |
| Operating Cash Flow | – | -$15,202 | -$28,010 | -$26,643 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | – | -$934 | -$123 | -$393 |
| Net Acquisitions | – | $0 | $6,000 | $0 |
| Inv. Purchases | – | $0 | $0 | $0 |
| Inv. Sales/Matur. | – | $0 | $1,090 | $0 |
| Other Inv. Act. | – | $1,341 | $235 | $267 |
| Investing Cash Flow | – | $407 | $7,202 | -$126 |
| Financing Activities | – | – | – | – |
| Debt Repay. | – | -$145 | -$896 | -$1,136 |
| Stock Issued | – | $9,490 | $0 | $36,568 |
| Stock Repurch. | – | $0 | -$124 | $0 |
| Dividends Paid | – | $0 | $0 | $0 |
| Other Fin. Act. | – | $9,500 | $4,137 | $40,657 |
| Financing Cash Flow | – | $9,355 | $3,241 | $39,521 |
| Forex Effect | – | -$1 | -$6 | $32 |
| Net Chg. in Cash | – | -$5,441 | -$17,573 | $12,784 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | – | $12,445 | $30,018 | $17,234 |
| End Cash | – | $7,004 | $12,445 | $30,018 |
| Free Cash Flow | – | -$16,101 | -$28,133 | -$27,036 |